Addressing Alzheimer's disease tangles: From NAP to AL-108

Illana Gozes*, Alistair Stewart, Bruce Morimoto, Anthony Fox, Karole Sutherland, Donald Schmechel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


AL-108 is the intranasal formulation of NAP (a peptide of eight amino acids, NAPVSIPQ). Phase IIa clinical results have recently shown that AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD). The clinical development of AL-108 has been based on extensive studies showing pre-clinical efficacy for NAP. NAP has demonstrated potent neuroprotective activity in vitro and in vivo. Its mechanism of action is thought to center on the modulation of microtubule stability in the face of outside damage. Such an effect on structures of such central importance in a broad range of cellular functions is thought to explain NAP's activity in wide ranging models of cellular damage and neurodegeneration. The following article reviews NAP's discovery and pharmacological characterization that has led to clinical development of a novel tangle-directed drug candidate.

Original languageEnglish
Pages (from-to)455-460
Number of pages6
JournalCurrent Alzheimer Research
Issue number5
StatePublished - Oct 2009


Dive into the research topics of 'Addressing Alzheimer's disease tangles: From NAP to AL-108'. Together they form a unique fingerprint.

Cite this